Gregory Craven, PhD

Covalent inhibition of mutant lysines in disease

We are exploiting covalent chemistry to target disease-causing lysine mutations, such as in cancer and immune disorders. We design and synthesize electrophilic small molecules that specifically target the lysine mutations that drive pathology. This approach offers a therapeutic angle for addressing gain-of-function mutations while mitigating adverse effects on healthy tissue.

Novel modalities for drug discovery

We’re developing innovative therapeutic strategies that use covalent chemistry to selectively induce high-affinity metal binding in disease-associated proteins. By harnessing underexplored covalent warheads and noncanonical binding mechanisms, we aim to modulate challenging protein targets. These approaches open new avenues for precision chemical biology and drug discovery.

Lipid metabolism in cancer immune evasion

We are investigating how dysregulated lipid metabolism enables cancer cells to evade immune surveillance. Using chemoproteomic and activity-based probes, we aim to map and modulate fatty acid-derived metabolites in tumor and immune cells. These tools provide new insights into metabolic immunosuppression and therapeutic vulnerabilities.